Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
406 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
HIV-1 Infection - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'HIV-1 Infection - Pipeline Review, H2 2015', provides an overview of the HIV-1 Infection's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 HIV-1 Infection Overview 7 Therapeutics Development 8 HIV-1 Infection - Therapeutics under Development by Companies 10 HIV-1 Infection - Therapeutics under Investigation by Universities/Institutes 15 HIV-1 Infection - Pipeline Products Glance 19 HIV-1 Infection - Products under Development by Companies 22 HIV-1 Infection - Products under Investigation by Universities/Institutes 29 HIV-1 Infection - Companies Involved in Therapeutics Development 34 HIV-1 Infection - Therapeutics Assessment 85 Drug Profiles 97 HIV-1 Infection - Recent Pipeline Updates 322 HIV-1 Infection - Dormant Projects 364 HIV-1 Infection - Discontinued Products 375 HIV-1 Infection - Product Development Milestones 377 Appendix 388
List of Tables
Number of Products under Development for HIV-1 Infection, H2 2015 25 Number of Products under Development for HIV-1 Infection - Comparative Analysis, H2 2015 26 Number of Products under Development by Companies, H2 2015 28 Number of Products under Development by Companies, H2 2015 (Contd..1) 29 Number of Products under Development by Companies, H2 2015 (Contd..2) 30 Number of Products under Development by Companies, H2 2015 (Contd..3) 31 Number of Products under Investigation by Universities/Institutes, H2 2015 33 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 34 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 35 Comparative Analysis by Late Stage Development, H2 2015 36 Comparative Analysis by Clinical Stage Development, H2 2015 37 Comparative Analysis by Early Stage Development, H2 2015 38 Products under Development by Companies, H2 2015 39 Products under Development by Companies, H2 2015 (Contd..1) 40 Products under Development by Companies, H2 2015 (Contd..2) 41 Products under Development by Companies, H2 2015 (Contd..3) 42 Products under Development by Companies, H2 2015 (Contd..4) 43 Products under Development by Companies, H2 2015 (Contd..5) 44 Products under Development by Companies, H2 2015 (Contd..6) 45 Products under Investigation by Universities/Institutes, H2 2015 46 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 47 Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 48 Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 49 Products under Investigation by Universities/Institutes, H2 2015 (Contd..4) 50 HIV-1 Infection - Pipeline by AltraVax Inc., H2 2015 51 HIV-1 Infection - Pipeline by Aphios Corporation, H2 2015 52 HIV-1 Infection - Pipeline by Argos Therapeutics, Inc., H2 2015 53 HIV-1 Infection - Pipeline by Arno Therapeutics, Inc., H2 2015 54 HIV-1 Infection - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015 55 HIV-1 Infection - Pipeline by Bionor Pharma ASA, H2 2015 56 HIV-1 Infection - Pipeline by Biosantech SA, H2 2015 57 HIV-1 Infection - Pipeline by Boehringer Ingelheim GmbH, H2 2015 58 HIV-1 Infection - Pipeline by Bristol-Myers Squibb Company, H2 2015 59 HIV-1 Infection - Pipeline by Chipscreen Biosciences Ltd, H2 2015 60 HIV-1 Infection - Pipeline by CompleGen, Inc., H2 2015 61 HIV-1 Infection - Pipeline by Critical Outcome Technologies Inc., H2 2015 62 HIV-1 Infection - Pipeline by Cytodyn Inc., H2 2015 63 HIV-1 Infection - Pipeline by Dong-A ST Co., Ltd., H2 2015 64 HIV-1 Infection - Pipeline by Enzo Biochem, Inc., H2 2015 65 HIV-1 Infection - Pipeline by Evofem, Inc., H2 2015 66 HIV-1 Infection - Pipeline by FIT Biotech Oy, H2 2015 67 HIV-1 Infection - Pipeline by Formune S.L., H2 2015 68 HIV-1 Infection - Pipeline by Frontier Biotechnologies Co., Ltd, H2 2015 69 HIV-1 Infection - Pipeline by GeneCure LLC, H2 2015 70 HIV-1 Infection - Pipeline by Genetic Immunity, Inc, H2 2015 71 HIV-1 Infection - Pipeline by Gilead Sciences, Inc., H2 2015 72 HIV-1 Infection - Pipeline by GlaxoSmithKline Plc, H2 2015 73 HIV-1 Infection - Pipeline by H-Phar S.A., H2 2015 74 HIV-1 Infection - Pipeline by Heat Biologics, Inc., H2 2015 75 HIV-1 Infection - Pipeline by InnaVirVax SA, H2 2015 76 HIV-1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 77 HIV-1 Infection - Pipeline by Johnson & Johnson, H2 2015 78 HIV-1 Infection - Pipeline by Merck & Co., Inc., H2 2015 79 HIV-1 Infection - Pipeline by Mologen AG, H2 2015 80 HIV-1 Infection - Pipeline by Mymetics Corporation, H2 2015 81 HIV-1 Infection - Pipeline by Myrexis, Inc., H2 2015 82 HIV-1 Infection - Pipeline by Novartis AG, H2 2015 83 HIV-1 Infection - Pipeline by Oncolys BioPharma Inc., H2 2015 84 HIV-1 Infection - Pipeline by Oncovir, Inc., H2 2015 85 HIV-1 Infection - Pipeline by OyaGen Inc., H2 2015 86 HIV-1 Infection - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2015 87 HIV-1 Infection - Pipeline by Pfizer Inc., H2 2015 88 HIV-1 Infection - Pipeline by Pharis Biotec GmbH, H2 2015 89 HIV-1 Infection - Pipeline by Profectus BioSciences, Inc., H2 2015 90 HIV-1 Infection - Pipeline by Sanofi Pasteur SA, H2 2015 91 HIV-1 Infection - Pipeline by Spider Biotech, H2 2015 92 HIV-1 Infection - Pipeline by Susavion Biosciences, Inc., H2 2015 93 HIV-1 Infection - Pipeline by TaiMed Biologics Inc., H2 2015 94 HIV-1 Infection - Pipeline by Takara Bio Inc., H2 2015 95 HIV-1 Infection - Pipeline by TGV-Laboratories, H2 2015 96 HIV-1 Infection - Pipeline by Theravectys SA, H2 2015 97 HIV-1 Infection - Pipeline by Tobira Therapeutics, Inc., H2 2015 98 HIV-1 Infection - Pipeline by United Biomedical, Inc., H2 2015 99 HIV-1 Infection - Pipeline by Vichem Chemie Research Ltd., H2 2015 100 HIV-1 Infection - Pipeline by ViiV Healthcare Limited, H2 2015 101 Assessment by Monotherapy Products, H2 2015 102 Assessment by Combination Products, H2 2015 103 Number of Products by Stage and Target, H2 2015 105 Number of Products by Stage and Mechanism of Action, H2 2015 108 Number of Products by Stage and Route of Administration, H2 2015 111 Number of Products by Stage and Molecule Type, H2 2015 113 HIV-1 Infection Therapeutics - Recent Pipeline Updates, H2 2015 339 HIV-1 Infection - Dormant Projects, H2 2015 381 HIV-1 Infection - Dormant Projects (Contd..1), H2 2015 382 HIV-1 Infection - Dormant Projects (Contd..2), H2 2015 383 HIV-1 Infection - Dormant Projects (Contd..3), H2 2015 384 HIV-1 Infection - Dormant Projects (Contd..4), H2 2015 385 HIV-1 Infection - Dormant Projects (Contd..5), H2 2015 386 HIV-1 Infection - Dormant Projects (Contd..6), H2 2015 387 HIV-1 Infection - Dormant Projects (Contd..7), H2 2015 388 HIV-1 Infection - Dormant Projects (Contd..8), H2 2015 389 HIV-1 Infection - Dormant Projects (Contd..9), H2 2015 390 HIV-1 Infection - Dormant Projects (Contd..10), H2 2015 391 HIV-1 Infection - Discontinued Products, H2 2015 392 HIV-1 Infection - Discontinued Products (Contd..1), H2 2015 393
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
